Advertisement

Topics

Progress Continues in HR+/HER2- Breast Cancer Paradigm

11:30 EDT 26 Mar 2019 | OncLive

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Original Article: Progress Continues in HR+/HER2- Breast Cancer Paradigm

NEXT ARTICLE

More From BioPortfolio on "Progress Continues in HR+/HER2- Breast Cancer Paradigm"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...